Phase III Trial of Cetuximab With Continuous or Intermittent Fluorouracil, Leucovorin, and Oxaliplatin (Nordic FLOX) Versus FLOX Alone in First-Line Treatment of Metastatic Colorectal Cancer – The NORDIC-VII Study




The NORDIC-VII Study

Tveit KM, Guren T, Glimelius B, Pfeiffer P, Sorbye H, Pyrhonen S, Sigurdsson F, Kure E, Ikdahl T, Skovlund E, Fokstuen T, Hansen F, Hofsli E, Birkemeyer E, Johnsson A, Starkhammar H, Yilmaz MK, Keldsen N, Erdal AB, Dajani O, Dahl O, Christoffersen T

PublisherAMER SOC CLINICAL ONCOLOGY

2012

Journal of Clinical Oncology

JOURNAL OF CLINICAL ONCOLOGY

J CLIN ONCOL

30

15

1755

1762

8

0732-183X

DOIhttps://doi.org/10.1200/JCO.2011.38.0915



Cetuximab did not add significant benefit to the Nordic FLOX regimen in first-line treatment of mCRC. J Clin Oncol 30:1755-1762. (c) 2012 by American Society of Clinical Oncology



Last updated on 2024-26-11 at 16:07